News

LATEST NEWS

Newronika News & Articles

9.8.2025

Newronika Appoints Keith Carlton as Executive Chairman to Reinforce Strategic Leadership

3.23.2025

Newronika Receives CE Mark Approval for AlphaDBS, Advancing Adaptive Deep Brain Stimulation for Parkinson's Disease

2.5.2025

Newronika Receives Investigational Device Exemption (IDE) from FDA to Initiate U.S. Clinical Trial of Adaptive DBS System

1.28.2025

Newronika Closes €13.6 Million Series B Financing to Accelerate Development of Adaptive DBS Platform

1.23.2025

New treatment prospects for people with Parkinson's thanks to international research funded by the Michael J. Fox Foundation for Parkinson's Research

1.22.2024

Newronika Sercures Initial €2 Million in Blended Finance from EIC Accelerator for Groundbreaking Parkinson’s Disease Research

3.9.2023

Newronika Secures 2.5 Million Euros Grant From EIC Accelerator

9.27.2019

Round d’investimento da 8,4 milioni per Newronika

9.26.2019

Medtech, la startup italiana Newronika chiude un round da 8,4 milioni

9.26.2019

Newronika Raises an 8.4M EUR Series-A Round

6.14.2016

Fondo Intesa Sanpaolo investe in Newronika

6.14.2016

Innogest e Intesa investono 1,7M in Newronika (Deep Brain Stimulation)

6.14.2016

Newronika chiude un round di venture capital

6.14.2016

Innogest, Intesa Sanpaolo e F3F investono 1,7 milioni in Newronika

6.14.2016

Neuromodulation Therapy Developer Newronika Raises €1.7M in Venture Capital

6.14.2016

Newronica, 1,7 milioni per la startup che combatte il Parkinson

12.2.2011

È italiano il primo pacemaker intelligente per il Parkinson

Join Our Journey

Setting the new standard of care together.

Partner with Newronika to bring the next generation of adaptive brain therapy to patients who need it most.

Contact Us

Let’s talk.

Whether you’re a clinician, researcher, investor, or partner — we’d love to hear from you.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

This device is CE-marked and commercially available in the European Economic Area. In the United States, the device is investigational and limited by federal law to investigational use only. It has not been cleared or approved by the U.S. Food and Drug Administration.